Zanubrutinib in patients with treatment‐naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded‐access study of 50 patients in the United States

• Jorge J Castillo,
• Edwin C Kingsley,
• Mohit Narang,
• Habte A Yimer,
• Constantin A Dasanu,
• Jason M Melear,
• Morton Coleman,
• Charles M Farber,
• Jonah Shulman,
• Emily H Mantovani,
• Xiaowei Zhang,
• Aileen Cohen,
• Jane Huang

Affiliations

Jorge J Castillo

Dana‐Farber Cancer Institute Boston Massachusetts USA

Edwin C Kingsley

Comprehensive CancerCenters of Nevada Las Vegas Nevada USA

Mohit Narang

US Oncology Research Maryland Hematology Oncology Columbia Maryland USA

Habte A Yimer

Texas Oncology US Oncology Research Tyler Texas USA

Constantin A Dasanu

Lucy Curci Cancer Center Eisenhower Health Rancho Mirage California USA

Jason M Melear

US Oncology Research Texas Oncology, Austin Midtown Austin Texas USA

Morton Coleman

Clinical Research Alliance Weill Cornell Medicine New York New York USA

Charles M Farber

Atlantic Hematology Oncology Morristown Medical Center Morristown New Jersey USA

Jonah Shulman

Icahn School of Medicine at Mount Sinai New York New York USA

Emily H Mantovani

BeiGene (Beijing) Co. Ltd. Beijing China and BeiGene Inc San Mateo California USA

Xiaowei Zhang

BeiGene (Beijing) Co. Ltd. Beijing China and BeiGene Inc San Mateo California USA

Aileen Cohen

BeiGene (Beijing) Co. Ltd. Beijing China and BeiGene Inc San Mateo California USA

Jane Huang

BeiGene (Beijing) Co. Ltd. Beijing China and BeiGene Inc San Mateo California USA